Black Diamond Therapeutics (BDTX) Payables (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Payables for 9 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 82.1% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (up 82.1% YoY), and the FY2025 full-year result was $579000.0, down 85.55% from the prior year.
• Payables declined to $1.4 million in Q2 2026 per BDTX's latest filing, from $3.0 million in the prior quarter.
• Across five years, Payables topped out at $5.8 million in Q3 2022 and bottomed at $579000.0 in Q4 2025.
• Historically, Payables has averaged $2.1 million across 5 years, with a median of $1.9 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Payables slumped 87.95% in 2023, then soared 184.01% in 2024.
• Over 5 years, Payables stood at $1.9 million in 2022, then grew by 23.81% to $2.3 million in 2023, then soared by 72.42% to $4.0 million in 2024, then tumbled by 85.55% to $579000.0 in 2025, then soared by 142.49% to $1.4 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $1.4 million, $3.0 million, and $579000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.